505(b)(2) Approval Strategy: The Complete Step-by-Step Guide to a Successful NDA Submission
The 505(b)(2) pathway is the pharmaceutical industry’s most capital-efficient regulatory route, and it is widely misunderstood. Ask ten drug developers […]
Cut Pharma Patent Litigation Costs From $50M to $5M: 3 Proven Strategies
The $50 Million Problem Nobody Wants to Talk About Most pharmaceutical executives treat patent litigation as a legal department problem.
Cut Pharma Patent Litigation Costs From $50M to $5M: 3 Proven Strategies Read Post »
Mark Cuban’s Cost-Plus Pricing Is Breaking Pharma’s Patent Playbook
The pharmaceutical industry’s patent defense system is a machine built on a single assumption: that the price of a drug
Mark Cuban’s Cost-Plus Pricing Is Breaking Pharma’s Patent Playbook Read Post »
PBMs, Formularies, and Rebates: The Pharma Executive’s Survival Guide
An investigative deep-dive for commercial leads, market access directors, and C-suite executives who negotiate with OptumRx, Express Scripts, and CVS
PBMs, Formularies, and Rebates: The Pharma Executive’s Survival Guide Read Post »
Should You File a Provisional Patent for Your Drug Invention? The Honest Answer
Every week, a medicinal chemistry team somewhere identifies a promising compound, runs it past the IP group, and asks a
Should You File a Provisional Patent for Your Drug Invention? The Honest Answer Read Post »
Don’t Wait for the Patent Cliff: Build Pharmaceutical Supply Chain Resilience Years Before Drug Patent Expiration
Every procurement director who has watched a blockbuster drug lose market exclusivity knows the same thing in hindsight: the scramble
Win the 180-Day FDA Exclusivity Race: Legal, Regulatory, and Commercial Playbook
The 180-day generic drug exclusivity period is, by raw financial math, one of the most lucrative regulatory prizes in the
Win the 180-Day FDA Exclusivity Race: Legal, Regulatory, and Commercial Playbook Read Post »
The PBM Endgame: What Mark Cuban Got Right (and Pharma Is Still Ignoring)
Mark Cuban launched Cost Plus Drugs in January 2022 with a simple premise: buy generic drugs at manufacturer cost, add
The PBM Endgame: What Mark Cuban Got Right (and Pharma Is Still Ignoring) Read Post »
Mark Cuban’s Cost Plus Drugs Is Killing Spread Pricing — Here’s What That Actually Means
A billionaire’s drugstore startup exposed the $6 billion arbitrage game inside America’s pharmacy benefit system. Now the entire supply chain
Mark Cuban’s Cost Plus Drugs Is Killing Spread Pricing — Here’s What That Actually Means Read Post »
